-DOCSTART- -X- O
Severe -X- _ O
influenza -X- _ O
infections -X- _ O
are -X- _ O
often -X- _ O
associated -X- _ O
with -X- _ O
the -X- _ O
excessive -X- _ O
induction -X- _ O
of -X- _ O
pro-inflammatory -X- _ O
cytokines -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
also -X- _ O
referred -X- _ O
to -X- _ O
as -X- _ O
“cytokine -X- _ O
storms”. -X- _ O
Several -X- _ O
studies -X- _ O
have -X- _ O
shown -X- _ O
that -X- _ O
cytokine -X- _ O
storms -X- _ O
are -X- _ O
directly -X- _ O
associated -X- _ O
with -X- _ O
influenza-induced -X- _ O
fatal -X- _ O
acute -X- _ O
lung -X- _ O
injury -X- _ O
and -X- _ O
acute -X- _ O
respiratory -X- _ O
distress -X- _ O
syndrome. -X- _ O
Due -X- _ O
to -X- _ O
the -X- _ O
narrow -X- _ O
administration -X- _ O
window -X- _ O
, -X- _ O
current -X- _ O
antiviral -X- _ O
therapies -X- _ O
are -X- _ O
often -X- _ O
inadequate. -X- _ O
The -X- _ O
efforts -X- _ O
to -X- _ O
use -X- _ O
immunomodulatory -X- _ O
agents -X- _ O
alone -X- _ O
or -X- _ O
in -X- _ O
combination -X- _ O
with -X- _ O
antiviral -X- _ O
agents -X- _ O
in -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
influenza -X- _ O
in -X- _ O
animal -X- _ O
models -X- _ O
have -X- _ O
resulted -X- _ O
in -X- _ O
the -X- _ O
achievement -X- _ O
of -X- _ O
protective -X- _ O
effects -X- _ O
accompanied -X- _ O
with -X- _ O
reduced -X- _ O
cytokine -X- _ O
production. -X- _ O
Currently -X- _ O
, -X- _ O
there -X- _ O
are -X- _ O
no -X- _ O
immunomodulatory -X- _ O
drugs -X- _ O
for -X- _ O
influenza -X- _ O
available -X- _ O
for -X- _ O
clinical -X- _ O
use. -X- _ O
Animal -X- _ O
models -X- _ O
, -X- _ O
despite -X- _ O
being -X- _ O
ideal -X- _ O
to -X- _ O
study -X- _ O
the -X- _ O
anti-inflammatory -X- _ O
responses -X- _ O
to -X- _ O
influenza -X- _ B-Patient
virus -X- _ I-Patient
infection -X- _ O
, -X- _ O
are -X- _ O
very -X- _ O
costly -X- _ O
and -X- _ O
time-consuming. -X- _ O
Therefore -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
an -X- _ O
urgent -X- _ O
need -X- _ O
to -X- _ O
establish -X- _ O
fast -X- _ O
and -X- _ O
economical -X- _ O
screening -X- _ O
methods -X- _ O
using -X- _ O
cell-based -X- _ O
models -X- _ O
to -X- _ O
screen -X- _ O
and -X- _ O
develop -X- _ O
novel -X- _ O
immunomodulatory -X- _ O
agents. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
screened -X- _ O
seven -X- _ B-Intervention
human -X- _ I-Intervention
cell -X- _ I-Intervention
lines -X- _ I-Intervention
and -X- _ O
found -X- _ O
that -X- _ O
the -X- _ O
human -X- _ B-Outcome
monocytic -X- _ I-Outcome
cell -X- _ I-Outcome
U937 -X- _ I-Outcome
supports -X- _ I-Outcome
the -X- _ I-Outcome
replication -X- _ I-Outcome
of -X- _ I-Outcome
different -X- _ I-Outcome
subtypes -X- _ I-Outcome
of -X- _ I-Outcome
influenza -X- _ I-Outcome
viruses -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
the -X- _ I-Outcome
production -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
important -X- _ I-Outcome
pro-inflammatory -X- _ I-Outcome
cytokines -X- _ I-Outcome
and -X- _ I-Outcome
was -X- _ I-Outcome
selected -X- _ I-Outcome
to -X- _ I-Outcome
develop -X- _ I-Outcome
the -X- _ I-Outcome
cell-based -X- _ I-Outcome
model. -X- _ I-Outcome
The -X- _ O
U937 -X- _ O
cell -X- _ O
model -X- _ O
was -X- _ O
validated -X- _ O
by -X- _ O
testing -X- _ O
a -X- _ O
panel -X- _ O
of -X- _ O
known -X- _ O
antiviral -X- _ O
and -X- _ O
immunomodulatory -X- _ O
agents -X- _ O
and -X- _ O
screening -X- _ O
a -X- _ O
drug -X- _ O
library -X- _ O
consisting -X- _ O
of -X- _ O
1280 -X- _ O
compounds -X- _ O
comprised -X- _ O
mostly -X- _ O
of -X- _ O
FDA-approved -X- _ O
drugs. -X- _ O
We -X- _ O
demonstrated -X- _ O
that -X- _ O
the -X- _ O
U937 -X- _ O
cell -X- _ O
model -X- _ O
is -X- _ O
robust -X- _ O
and -X- _ O
suitable -X- _ O
for -X- _ O
the -X- _ O
high-throughput -X- _ O
screening -X- _ O
of -X- _ O
immunomodulators -X- _ O
and -X- _ O
antivirals -X- _ O
against -X- _ O
influenza -X- _ O
infection. -X- _ O
ELECTRONIC -X- _ O
SUPPLEMENTARY -X- _ O
MATERIAL -X- _ O
: -X- _ O
The -X- _ O
online -X- _ O
version -X- _ O
of -X- _ O
this -X- _ O
article -X- _ O
( -X- _ O
10.1007 -X- _ O
/ -X- _ O
s12250-019-00145-w -X- _ O
) -X- _ O
contains -X- _ O
supplementary -X- _ O
material -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
available -X- _ O
to -X- _ O
authorized -X- _ O
users -X- _ O
. -X- _ O

